Infliximab

In this video, Christopher Sayed, MD, discusses “pearls” from the advanced management of hidradenitis suppurativa symposium at the American Academy of Dermatology Annual Meeting.

Patients with Crohn’s disease who stopped infliximab had a significantly higher risk of relapse vs. those who continued combination therapy, according to results presented at the Congress of the European Crohn’s and Colitis Organization.

The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis.

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.

Early infliximab therapy initiation following surgery may result in long-term fistula healing among patients with perianal fistulizing Crohn’s disease, according to research published in BMC Gastroenterology.

Proactive therapeutic drug monitoring sustained disease control without disease worsening among patients with immune-mediated inflammatory diseases undergoing infliximab maintenance therapy, according to study results.

Compared with placebo, most biologic and small molecule therapies correlated with superiority for the induction of remission in moderate to severe ulcerative colitis, according to research published in Gut.

Withdrawal and reinitiation of treatment with most biologic agents had minimal impact on efficacy in plaque psoriasis, according to a study.

Therapeutic drug monitoring, in which serum levels are regularly checked to adjust dose and intervals, is more effective at controlling disease than standard therapy with infliximab, according to data presented at ACR Convergence 2021.

LAS VEGAS – Physicians should remember there are many points to consider when selecting the right treatment for patients with ulcerative colitis, according to a presenter at the ACG Annual Scientific Meeting.